过去二十年银屑病患者代谢综合征的全球患病率:当前证据
该系统综述与Meta分析检索五个数据库至2021年9月,评估银屑病患者代谢综合征全球患病率;总体为32%(95%CI 0.26-0.38),成人32%(95%CI 0.29-0.36),儿童青少年9%(95%CI 0.00-0.18),拉丁美洲最高47%(95%CI 0.43-0.51),北美最低26%(95%CI 0.16-0.37)。
要点
- 银屑病患者代谢综合征全球患病率为32%(95%CI 0.26-0.38)。
- 成人患病率32%(95%CI 0.29-0.36),儿童青少年9%(95%CI 0.00-0.18)。
- 拉丁美洲患病率最高47%(95%CI 0.43-0.51),北美最低26%(95%CI 0.16-0.37)。
核心结论
- 银屑病患者代谢综合征全球患病率为32%(95%CI 0.26-0.38),作者认为应在银屑病患者中适当识别和管理代谢综合征。
研究设计与样本
- 系统综述与Meta分析,检索五个数据库从建库至2021年9月,使用AHRQ和NOS工具评估观察性研究质量,用Stata SE 15.1进行数据分析。
主要发现
- 银屑病患者代谢综合征全球患病率为32%(95%CI 0.26-0.38)。
- 成人患病率为32%(95%CI 0.29-0.36),儿童和青少年为9%(95%CI 0.00-0.18)。
- 拉丁美洲患病率最高为47%(95%CI 0.43-0.51),北美最低为26%(95%CI 0.16-0.37)。
- 寻常型银屑病患者患病率为29%(95%CI 0.23-0.35),重度银屑病患者为37%(95%CI 0.27-0.46),均高于其他银屑病类型。
临床怎么用
- 作者认为,在银屑病患者中应适当识别和管理代谢综合征。
- 作者指出,需要更多基于人群的前瞻性观察性研究来阐明银屑病患者共存代谢综合征的机制。
局限性
- 作者指出需要更多基于人群的前瞻性观察性研究来阐明银屑病患者共存代谢综合征的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with psoriasis are at an increased risk of metabolic syndrome (MetS); however, a systematic analysis of its global prevalence has not been performed to date. Here, we performed a systematic review and meta-analysis to assess the prevalence of MetS among patients with psoriasis. We searched five databases from inception through September 2021 and used the Agency for Healthcare Research and Quality (AHRQ) and Newcastle-Ottawa Scale (NOS) tools to assess observational study quality. Stata SE 15.1 was used to perform the data analysis. Subgroup, meta-regression and sensitivity analyses were used to evaluate interstudy heterogeneity. Publication bias was evaluated using Egger's and Begg's linear tests. The global prevalence of MetS in patients with psoriasis was 32% (95% confidence interval [CI], 0.26-0.38). The prevalence in adults was 32% (95% CI, 0.29-0.36), while that in children and adolescents was 9% (95% CI, 0.00-0.18). Latin America had the highest prevalence of 47% (95% CI, 0.43-0.51), whereas North America had the lowest prevalence of 26% (95% CI, 0.16-0.37). Patients with psoriasis vulgaris (29%; 95% CI, 0.23-0.35) or severe psoriasis (37%; 95% CI, 0.27-0.46) had a higher prevalence of MetS than those with other psoriasis types. These findings suggest that MetS should be appropriately recognized and managed in patients with psoriasis. More population-based prospective observational studies are required to elucidate the mechanisms underlying the coexistence of MetS in patients with psoriasis.
引用
- Liu L, Cai XC, Sun XY, et al. Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence. J Eur Acad Dermatol Venereol. 2022. PMID: 35666614. doi:10.1111/jdv.18296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。